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The essential role of MAGI2 in podocytes is reflected by the severe glomerulosclerosis 
phenotypes of both MAGI2 knockout mice and of humans with congenital nephrotic 
syndrome (CNS) caused by mutations in MAGI2.  Here, we show MAGI2 directly binds 
the Rap1 guanine nucleotide exchange factor, RapGEF2, and that this interaction is lost 
when expressing MAGI2 CNS variants. Co-expression of RapGEF2 with wild-type 
MAGI2, but not MAGI2 CNS variants, enhanced activation of the small GTPase Rap1, a 
central signaling node in podocytes. In mice, podocyte-specific RapGEF2 deletion resulted 
in spontaneous glomerulosclerosis, with qualitative glomerular features comparable to 
MAGI2 knockout mice. Knockdown of RapGEF2 or MAGI2 in human podocytes caused 
similar reductions in levels of Rap1 activation and Rap1-mediated downstream signaling. 
Furthermore, human podocytes expressing MAGI2 CNS variants show dramatically 
decreased actin polymerization and abnormal cellular morphology that is completely 
rescued by pharmacological activation of Rap1 via a non-MAGI2 dependent upstream 
pathway. Finally, immunostaining of kidney sections from CNS patients with MAGI2 
mutations showed reduced podocyte Rap1-mediated signaling. We conclude that MAGI2-
RapGEF2-Rap1 signaling is essential for normal podocyte function and that disruption of 
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 Membrane associated guanylate kinase 2 (MAGI2) belongs to the MAGUK family 
of scaffolding proteins. It is composed of five PDZ domains, two WW domains, a Src 
homology (SH3) domain, and a catalytically inactive guanylate kinase domain. These 
multiple protein-protein interacting domains predict dual functions as a molecular scaffold 
and signaling hub. The MAGI subfamily has three members, designated MAGI1, MAGI2, 
and MAGI3, which share identical protein domains and similar molecular structure. In 
kidney, MAGI2 is exclusively expressed in podocytes 1, the terminally differentiated 
epithelial cells that line the outer aspect of the glomerular basement membrane and 
regulate the filtration of blood to form urine. Within the podocyte, it is specifically 
expressed at the slit diaphragm 1,2, a specialized cell-cell junction that bridges adjacent 
interdigitating podocyte foot processes. All forms of human proteinuric kidney disease, 
regardless of specific etiology, result in podocyte injury with loss of normal foot process 
architecture, a pathological process known as effacement.  
 Multiple recent individual MAGI2 knockout mouse models all demonstrate the 
gene’s essential roles in podocyte development and function 3-6. Two global knockout 
mouse models die within the first 24 hours after birth from anuric renal failure with 
absence of slit diaphragm formation 3,5. The third global knockout model 4 and a podocyte-
specific knockout 6 both develop severe focal segmental and global glomerulosclerosis 
with renal failure and early lethality. In humans as well, convincing disease-causing 
mutations in MAGI2 give rise to congenital nephrotic syndrome (CNS) 7,8. Most cases 
present with severe nephrotic syndrome in the first few months of life. While these 
findings establish the critical role of MAGI2 in proper podocyte function in mice and 
humans, the underlying mechanisms are poorly understood. 
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 MAGI proteins have previously been implicated as upstream activators of the small 
GTPase Rap1 9,10, which regulates multiple essential downstream signaling pathways in 
podocytes including activation of 1 integrin 11. In fact, mice with reduced podocyte Rap1 
expression develop severe glomeruloscerosis and early death from renal failure by 8 weeks 
of age 11. Rap1 cycles between an active GTP-bound form and an inactive GDP-bound 
form.  The balance between active and inactive Rap1 is tightly regulated by numerous 
upstream factors including guanine nucleotide exchange factors (GEFs), which turn on 
signaling by catalyzing the exchange of GDP to GTP, and GTPase activating proteins 
(GAPs), which terminate signaling by hydrolyzing GTP to GDP 12. Rap1-specific GEFs 
include RapGEF1, RapGEF2 (PDZ-GEF1), RapGEF3 (EPAC1), RapGEF4 (EPAC2), 
RapGEF5, and RapGEF6 (PDZ-GEF2). RapGEF2 has been shown to bind MAGI proteins 
10, to have enriched expression in the mammalian glomerulus 13, and to be important in 
maintenance of the glomerular filtration barrier in zebrafish 14. With this background, we 
aimed to investigate the interaction between RapGEF2 and MAGI2 as potential upstream 
regulator of podocyte Rap1 activation. 
 
Results: 
MAGI2 variants that cause congenital nephrotic syndrome fail to interact with RapGEF2 
and are unable to induce Rap1 activation 
 Two homozygous truncating point mutations in the human MAGI2 gene (pGly39* 
and pTyr746*) have been identified as directly causative of CNS 7 (comparison of domain 
organizations, figure 1A). Both of the affected patients presented with severe CNS early in 
childhood 7. Reciprocal co-immunoprecipitation experiments performed between FLAG-
RapGEF2 and full-length GFP-MAGI2 show a robust protein:protein interaction (figure 
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1B). This protein interaction, however, is completely lost when substituting either of the 
GFP-tagged MAGI2 disease causing variants. GFP-Toca, used as a negative control, also 
failed to interact with FLAG-RapGEF2. 
 To look for a functional consequence to the loss of this interaction, we tested the 
ability of each to induce Rap1 activation (figure 2A). We utilized calcium switch as a 
means to induce cellular Rap1 activation using a previously established protocol 9,10.  
Confluent transfected 293T cells were exposed briefly to calcium chelation to disrupt 
intercellular contacts (EGTA washout), after which full calcium containing medium was 
restored (calcium switch). Consistent with published data, we found a general increase in 
levels of Rap1 activation in all transfectants after calcium switch (figure 2A). However, 
this effect was dramatically enhanced in 293T cells expressing both RapGEF2 and full-
length MAGI2, but was not present in cells expressing both RapGEF2 and either of the 
MAGI2 mutant variants. Previous work had also implicated MAGI1 as a regulator of 
podocyte Rap1 activation 10.  However, using an identical calcium switch system, the 
combined expression of MAGI1 and RapGEF2 did not augment Rap1 activation beyond 
baseline (figure 2B). Overall, these findings demonstrate that the interaction of MAGI2, 
but not disease causing MAGI2 variants, with RapGEF2 functions as a potent stimulus for 
Rap1 activation.    
 
Podocyte-specific RapGEF2 KO mice develop FSGS with comparable qualitative 
glomerular features compared to MAGI2 KO mice 
 We next performed detailed immunofluorescence studies to localize RapGEF2 
protein within wild-type kidney (figure 3A). Unlike MAGI2, RapGEF2 is robustly 
expressed in both the glomerular and tubular compartments. Within the glomerulus, it is 
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strongly expressed in podocytes. Its cellular localization within the podocyte is complex, 
with expression predominantly in the cytoplasm, where it co-localizes with podocyte 
cytoplasmic marker nestin.   
We hypothesized that if RapGEF2 function was mediated by its interaction with 
MAGI2, then RapGEF2 knockout mice, similar to MAGI2 deficient mice, would 
demonstrate severe podocyte dysfunction. Because, global RapGEF2 knockout mice are 
early embryonic lethal 15, we bred a conditional floxed RapGEF2 knockout mouse line 15 
to a transgenic mouse line that expresses cre recombinase under podocyte-specific 
promoter podocin 16. This allowed the generation of podocyte-specific knockout of 
RapGEF2. RapGEF2 immunostaining verifies loss of glomerular, but preservation of 
tubular, RapGEF2 expression in these mice (figure 3B).  
Podocyte-specific RapGEF2 KO mice develop overt proteinuria at between 6 and 
16 weeks of age (figure 4A) with progressive glomerulosclerosis and severe proteinuria by 
20 weeks of age (figure 4B).  The renal phenotype is comparable to that described for 
podocyte-specific MAGI2 KO 6 and global MAGI2 KO mice 4, although onset of 
proteinuria for the RapGEF2 model is later and glomerulosclerosis scores overall less 
severe (figure 4C).  Renal histological analysis reveals similar qualitative glomerular 
features between RapGEF2 and MAGI2 models that include focal segmental and global 
glomerulosclerosis, mesangial expansion, podocyte loss, and glomerular epithelial cell 
proliferation with pseudocrescent formation (figure 4D). Electron microscopic features are 
similar between the two models: diffuse severe foot process effacement with basal actin 
matting, simplification of overall podocyte cellular shape, loss of normal primary and 
secondary process architecture, and cytoplasmic vacuolization (figure 4E). Podocyte loss is 
a major driving force for development of glomerulosclerosis 17.  To quantify podocyte 
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depletion in our model, we calculated the number of WT1-positive cells per glomerular tuft 
area (figure 4F). Consistent with the severity of their pathologic findings, podocyte loss 
was greater in MAGI2 KO mice than in RapGEF2 KO mice, but both models showed 
substantially fewer podocytes compared to control mice.    
 
RapGEF2 or MAGI2 knockdown in podocytes similarly diminish Rap1-GTP activation and 
signaling 
We hypothesized that podocyte dysfunction in both the RapGEF2 and MAGI2 KO 
mouse models was caused by similar reductions in podocyte Rap1 activation and 
downstream Rap1 signaling pathway activation. To investigate this possibility, we 
transduced a shRNA expression plasmid that targeted either RapGEF2 or MAGI2 RNA 
into a conditionally immortalized human podocyte cell line 18. To eliminate the possibility 
of non-specific off target effects, we utilized two different hairpins per gene, each with a 
distinct RNA target sequence.  In this way, we generated two distinct RapGEF2 
knockdown and two distinct MAGI2 knockdown podocyte cell lines. By western blotting, 
we confirmed severely reduced RapGEF2 or MAGI2 protein expression in each of the 
knockdown podocyte cell lines compared to control podocytes that were transduced with a 
scrambled shRNA expression plasmid (figure 5A).  
In the setting of calcium switch, RapGEF2 and MAGI2 knockdown podocytes 
showed similar reductions in the level of Rap1 activation (figure 5A) as well as 
dramatically reduced levels of essential Rap1 mediated downstream signals including 1 
integrin activation and Erk phosphorylation (figure 5B). To detect levels of activated 1 
integrin, native PAGE electrophoresis (non-reducing and non-denaturing sample buffer) 
was utilized; under these conditions, the monoclonal antibody 12G10 specifically detects 
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the activated form of 1 integrin. Next, we studied cellular migration rates, which are 
substantially reduced in podocytes that have diminished cellular Rap1 activation 11, a 
reliable phenotype observed in podocyte-specific knockdown of other genes known to 
cause nephrotic syndrome 7,19,20. Again, RapGEF2 and MAGI2 knockdown podocyte cell 
lines behaved similarly, each showing dramatic reductions in migratory rates (figure 5C). 
Diminished cellular Rap1 activation was also previously reported to enhance podocyte 
susceptibility to apoptosis 11. By Annexin PI staining, we found comparable high rates of 
podocyte apoptosis under basal condition for both RapGEF2 and MAGI2 knockdown 
podocytes compared to control cells (figure 6A, 6B). Taken together, these data 
demonstrate that loss of either RapGEF2 or MAGI2 in podocytes causes disruption to 
Rap1 activation and downstream signaling.  
 
Human podocytes that express MAGI2 CNS causing variants are phenotypically rescued 
by pharmacological activation of Rap1  
Here, we generated individual human podocyte cell lines that express FLAG-
tagged wild type MAGI2 and each of the FLAG-tagged CNS MAGI2 human mutant 
variants (pGly39* and pTyr746*). This was accomplished by transduction of a lentiviral 
expression plasmid into human podocytes under permissive conditions (vector backbone 
pSF-Lenti), followed by selection with puromycin. Robust expression of wild type and 
mutant versions of MAGI2 in transduced podocytes is shown by immunofluorescence 
using an anti-FLAG antibody as compared to control vector-alone transduced podocytes 
(figure 7A).  Interestingly, while wild type MAGI2 strongly localized to sites of 
intercellular contact, both of the MAG2 mutant proteins were completely mislocalized, 
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showing robust accumulation in cytoplasmic vesicles and almost no expression at 
intercellular contacts. Control podocytes lacked any immunoreactivity. 
          Differentiated podocytes that expressed either of the human MAGI2 disease causing 
variants, demonstrated severe abnormalities of cellular morphology, including an 
elongated cellular shape and dramatically diminished actin polymerization (figure 7B, C).  
Vector-alone and wild type MAGI2 transduced podocyte lines each demonstrated normal 
morphology and overall actin content. Podocytes expressing either of the MAGI2 disease 
causing mutations show diminished basal Rap1 activation compared to podocytes 
expressing wild type MAGI2 (figure 7D). To show that inactivation of the MAGI2-
RapGEF2-Rap1 signal is the cause of podocyte dysfunction induced by disease causing 
MAGI2 mutations, rescue experiments were performed using pharmacological activation 
of Rap1 via a non-MAGI2 dependent upstream pathway. Individual podocyte cell lines 
were split from the same flask prior to moving to 37°C, and then maintained under non-
permissive conditions for seven days, either with or without the potent Rap1 activating 
drug 8-pCPT-2′-O-Me-cAMP (10M) 21. In the presence of the drug, levels of activated 
Rap1 were dramatically increased in the mutant MAGI2 expressing podocyte cell lines to 
levels similar to wild type MAGI2 expressing cells (figure 7D). Impressively, mutant 
MAGI2 transduced podocytes were completely rescued by pharmacological Rap1 
activation including normalization of cellular shape and robust levels of actin 
polymerization (figure 7B, C). These findings suggest that inactivation of RapGEF2-Rap1 
signaling is an important cause of the renal phenotype induced by MAGI2 CNS mutations. 
  
Immunostaining of kidney sections from CNS patients with MAGI2 mutations is consistent 
with reduced glomerular Rap1GTPase mediated signaling  
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 To corroborate our findings in humans, we performed immunohistochemistry on 
kidney sections from patients with CNS due to mutations in MAGI2 8. Because direct 
staining for activated Rap1 is not feasible, we investigated activation of the Rap1-mediated 
downstream signal Erk1/2 (figure 8A, 8B). While phosphorylated Erk1/2 is highly 
enriched in podocytes of control kidney, it is essentially undetectable in podocytes from 
patients with CNS caused by MAGI2 mutations. Levels of Erk1/2 phosphorylation were 
only moderately reduced in podocytes from idiopathic FSGS patients compared to 
controls, suggesting that such dramatic loss of podocyte Erk1/2 phosphorylation cannot be 
generalized to all forms of podocyte injury.  Importantly, total Erk1/2 was ubiquitously 
expressed in all samples, including substantially in podocytes, suggesting that podocyte 
loss is not the main explanation for our observed reductions in phosphorylated Erk1/2 
staining.  Overall, these findings are consistent with reduced levels of podocyte Rap1 
activation in CNS patients harboring mutations in MAGI2. 
 
Discussion: 
 In the current work, we propose a novel mechanism of podocyte injury in patients 
with CNS caused by mutations in MAGI2 (figure 9). In normal podocytes under 
physiological conditions, MAGI2 interacts directly with RapGEF2, and this interaction is 
required to sustain adequate levels of Rap1 activation and Rap1-mediated downstream 
signaling. In patients with MAGI2 mutations, however, the interaction between MAGI2 
and RapGEF2 is lost, causing inability of this complex to activate Rap1. Over time, the 
resulting inadequate levels of podocyte Rap1 activation as well as Rap1-mediated 
downstream signaling induce podocyte injury and mediate FSGS. We conclude that under 
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the basal condition, the interaction between MAGI2 and RapGEF2 is a critical upstream 
signal for Rap1 activation in podocytes. 
 The FSGS phenotypes of global and podocyte-specific MAGI2 KO mice 4,6 are 
more severe than for podocyte-specific RapGEF2 KO mice. This difference is reflected in 
a more completely penetrant phenotype, earlier age of onset of proteinuria, more severe 
pathological findings including higher glomerulosclerosis, and earlier lethality. There are 
several potential explanations for this finding.  First, it is likely that MAGI2 has important 
functions beyond its interaction with RapGEF2. MAGI2 protein contains multiple protein 
interacting domains (PDZ and WW) and mediates numerous protein-protein interactions 
essential for proper podocyte function 2,22,23. For example, MAGI2 directly interacts with 
nephrin and forms part of the intricate cytoplasmic protein complex at the slit diaphragm 
2,24.  Two of the three described global MAGI2 knockout mouse models have demonstrated 
alterations in nephrin expression and localization, suggesting that MAGI2 may have a role 
in nephrin stability and/or signaling 4,5. Another proposed function of MAGI2, via its direct 
interaction with dendrin, is as regulator of Hippo signaling 3,25, which has recently been 
shown to be critical to podocyte function 26. In podocyte-specific MAGI2 knockout mice, 
loss of MAGI2 induced dendrin translocation to the nucleus, alterations in the Hippo 
regulator YAP, and podocyte apoptosis 6. Beyond these known interactions with nephrin 
and dendrin, MAGI2 may mediate other yet uncharacterized protein interactions governing 
podocyte maintenance.  A second potential explanation for the milder phenotype of 
RapGEF2 KO mice is redundancy in the network of proteins that regulate Rap1 function. 
RapGEF2 loss of function, under the appropriate conditions, might be compensated by 
upregulation of other Rap1 activators including other Rap1-specific GEFs. A suitable 
candidate activator is RapGEF6, which is structurally similar to RapGEF2 27.  Ongoing 
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studies will look at whether RapGEF6 is expressed in podocytes and if so, whether it can 
also activate Rap1 by a direct interaction with MAGI2.   
 We acknowledge that because several upstream signaling cascades can induce 
Erk1/2 phosphorylation, measuring its staining intensity as a secondary read-out for levels 
of Rap1 activation has limitations.  However, our available starting material from MAGI2 
CNS patients was limited to paraffin embedded slides only.  Because there is no 
technically feasible way to stain directly for levels of Rap1 activation on such sections, our 
best option was to assay for a major downstream Rap1-mediated signal as a surrogate read-
out. We selected to use immunostaining for Erk1/2 phosphorylation because it is a major 
downstream target of Rap1 that can be reliably detected on paraffin embedded material by 
a well-characterized commercially available antibody and is also relatively podocyte-
specific in kidney.  To minimize the possibility of a secondary effect, we analyzed levels 
of podocyte Erk1/2 phosphorylation in multiple cases of idiopathic FSGS and compared 
them to MAGI2 CNS.  Levels of podocyte Erk1/2 phosphorylation were uniformly lower 
in MAGI2 CNS compared to idiopathic FSGS, suggesting the effect to be specific and 
could not be generalized to all forms of podocyte injury.  Overall, these findings are 
consistent with our observations in MAGI2 knockdown cultured podocytes, where it was 
technically possible to demonstrate that diminished Erk1/2 phosphorylation was 
downstream of reductions in Rap1 activation.    
 MAGI2 expression is one of the most dramatically downregulated of all podocyte-
expressed genes in human proteinuric kidney diseases including diabetic nephropathy and 
idiopathic FSGS (5, nephroseq database). Levels of podocyte activated Rap1 are likewise 
reduced in the same conditions 11. Further studies will be required to determine whether 
reduced expression of MAGI2 is a cause of diminished podocyte Rap1 in these diseases. 
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What is clear, however, is that the activation state of podocyte Rap1 is tightly regulated 
both under the basal condition and in the setting of podocyte injury. Importantly, several of 
the regulatory proteins located upstream of Rap1, including MAGI2 but not RapGEF2, are 
mainly podocyte-specific. An innovative therapeutic approach would be to 
pharmacologically target such podocyte-specific regulatory proteins. This targeted 
approach would increase levels of activated Rap1 specifically in podocytes and thereby 




Podocin-cre transgenic mice 16, floxed RapGEF2 conditional knockout mice 15, and global 
MAGI2 knockout mice 4 were previously described.  All mice were genotyped according 
to their previously described protocols. 
 
Human kidney samples 
We analyzed paraffin embedded kidney sections (one biopsy, one nephrectomy) from two 
patients with CNS caused by MAGI2 mutations 8. Paraffin embedded deidentified human 
kidney sections from archived human biopsies were provided by Vivette D’Agati with 
appropriate IRB approval (five separate cases). All biopsies were clinically indicated and 
carried a confirmed pathological diagnosis of idiopathic FSGS. Paraffin-embedded normal 
human kidney sections were obtained from nephrectomy samples from the Department of 
Pathology at Icahn School of Medicine. In all cases, only remaining tissue not required for 





The following antibodies were used: Rap1 (ThermoFisher Scientific, 16120), total Erk1/2 
(Cell Signaling Technology, 137F5), phospho-Erk1/2 (Cell Signaling Technology 
(Thr202/Tyr204) D13.14.4E), activated β1 integrin (Millipore, clone 12G10), total β1 
integrin (BD Biosciences, clone 18), MAGI2 (Sigma Aldrich, M2441), RapGEF2 (Sigma 
Aldrich, clone 1E8, WB), RapGEF2 (Lifespan Biosciences, LS-B12608, IF), WT1 
(Abcam, CAN-R9 (IHC)-56-2), nestin (BD Biosciences, 556309), FLAG (Sigma Aldrich, 
M2), GFP (Clontech, 632377).  
 
Plasmids 
Expression plasmids for GFP-MAGI2 wild type, GFP-MAGI2 pGly39*, and GFP-MAGI2 
pTry746* were previously described 7. The expression plasmids for FLAG-RapGEF2 28 
and myc-MAGI1 9 have been described previously. The lentiviral expression plasmid also 
encoding puromycin resistance, pSF-Lenti, was purchased from Sigma-Millipore.  FLAG-
MAGI2 wild type, FLAG-MAGI2 pGly39*, and FLAG-MAGI2 pTyr746* were 
synthesized and cloned into pSF-Lenti by GenScript Biotech Corporation. 
 
Histopathology and immunohistochemistry 
All kidneys were perfused in vivo with 4% PFA. For histological analysis, kidneys were 
left in PFA overnight and then embedded in paraffin. Sections were cut at 2 μm and 
stained with PAS. For IF, kidneys were fixed in PFA for 4 hours, transferred to 18% 
sucrose overnight, and then flash-frozen in OCT medium. For electron microscopy, 
samples were cut into 1-mm cubes and fixed overnight in 2.5% glutaraldehyde before 




Podocyte cell culture 
A conditionally immortalized human podocyte cell line was propagated and differentiated 
as has been described previously 18. 
 
Lentiviral infection and production 
All shRNA plasmids were purchased from Origene, already cloned into the pGFP-C-
shLenti backbone: RapGEF2 shRNA plasmids (TL316875), MAGI2 shRNA plasmids 
(TL311600), and scrambled shRNA control (TR30021).  Hairpin sequences specific for 
human RapGEF2 are as follows: CAATGTCAGTGAGGCGAGAACTCTGTGCT (#1) 
and TGGTCAGTCTCAAGATGACAGCATAGTAG (#2). Hairpin sequences specific for 
human MAGI2 are as follows: GAACCTGAGCCATACAGAAGTAGTGGATA (#1) and 
TCTACTTCATTGACCATAACACAAAGACA (#2). FLAG-tagged wild type and mutant 
MAGI2 lentiviral expression plasmids were synthesized and cloned into pSF-Lenti by 
GenScript Biotech Corporation. All lentiviral preparation and infections were performed as 
previously described 29.  Infections were done at the permissive temperature in 
conditionally immortalized human podocytes, and then stable cell lines were established 
by selection with puromycin at a concentration of 1-2 ug/ml. Knockdown and control 
transduced cell lines were grown at 37°C for at least 1 week prior to use in experiments.  
 
Reciprocal co-immunoprecipitations 
Plates of 293T cells were individually transfected with FLAG-RapGEF2, GFP-MAGI2 
wild type, GFP-MAGI2 pGly39*, and GFP-MAGI2 pTry746*. Reciprocal co-
immunoprecipitations were performed using antibodies to each protein’s tag (either GFP-
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agarose (Allele Biotechnology) or Anti-FLAG M2 affinity gel (Sigma Aldrich). Total 
cellular lysates were harvested in RIPA buffer, combined at equal concentrations, and then 
incubated overnight with either the GFP-agarose or FLAG gel.  Beads were washed with 
RIPA buffer x 3 and then boiled. Western blotting was performed on resulting eluates and 
on input lysates. 
.   
Rap1-GTP pull downs 
Relative levels of active Rap1 were assessed by pull-downs using a GST-tagged fusion 
protein, corresponding to amino acids 788–884 of the human RalGDS-RAP-binding 
domain bound to glutathione-agarose.  Experiments were performed using the Active Rap1 
Pull-down and Detection Kit, (ThermoFisher Scientific, 16120). 
 
Calcium switch 
Confluent cells were serum-deprived overnight in medium containing 1% serum. To 
chelate extracellular calcium, cells were exposed to 1 mM EGTA (293T cells) or 2 mM 
EGTA (podocytes) for 2 minutes (293T cells) or 10 minutes (podocyes). Cells were 




Staining was performed with Annexin V APC (eBioscience) and 7-AAD (eBioscience).  






Differentiated podocytes were plated to complete confluence on collagen type I–coated 6-
well plates. A scratch was created using a 200-μl sterile pipette, and loosely adherent cells 
were removed by washing. At specific time intervals, images were obtained at several 
fixed locations along the scratch.  Percent wound closure was calculated using ImageJ 
processing program. 
 
Quantification of immunostaining 
Immunostained images with a final magnitude of 400X were obtained.  The level of 
immunostaining was measured using ImageJ software.  First, acquired images were 
converted to 8-bit grayscale. Glomerular regions were selected for measurement of area 
and integrated intensity.  Background intensity was measured by selecting three distinct 
areas that showed no staining.  The corrected optical density was calculated as previously 
described 30. 
 
Calculation of podocyte number 
The number of WT1-positive cells per glomerular tuft was determined for approximately 
20 glomeruli per animal (n=3 mice per group, total of 60 glomeruli per group).  Glomeruli 
were selected at random. Glomerular area was calculated using ImageJ software. 
 
Pharmacological Rap1 Activation 
Podocytes were split into two flasks at time of thermoshift to 37°C and allowed to 
differentiate for one day. At this point, we added the potent Rap1 activating drug, 8-pCPT-
2′-O-Me-cAMP (from Sigma Aldrich) at a concentration of 10 M to one flask and vehicle 
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only to the other. Cells were allowed to continue to differentiate under these conditions for 
an additional seven days prior to performing experiments. The drug 8-pCPT-2′-O-Me-




All experiments were repeated at least three or more times. Bar graphs represent combined 
results from all experiments. All data is represented as mean ± SEM. Statistical 
significance was determined by utilizing the 2-tailed Student’s t test. A P value of less than 




All mouse studies were approved by the IACUC at Icahn School of Medicine at Mount 
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Figure 1. MAGI2, but not variants that cause congenital nephrotic syndrome, 
interacts with RapGEF2. (A) Schematic representation of protein domain organization of 
wild type MAGI2 and two of its disease-causing variants, Gly39* and Tyr746*.  Each 
variant carries a homozygous truncating point mutation.  Image was generated using the 
Simple Modular Architecture Research Tool (SMART) web resource and then modified. 
(B) Reciprocal co-immunoprecipitations between FLAG-tagged RapGEF2 and GFP-
tagged MAGI2 was performed using antibodies to their tags. FLAG-RapGEF2 and the 
indicated GFP-tagged MAGI2 protein lysates were mixed at equal concentration and 
incubated overnight with FLAG (upper blot) or GFP (lower blot) antibodies bound to 
agarose. A robust interaction is present between RapGEF2 and wild type MAGI2, but is 
completely lost for MAGI2 mutant variants or for the negative control, GFP-Toca. 
Predicted molecular weights for each protein are as follows: GFP-MAGI2 WT, 185 kDa; 
GFP-MAGI2 Gly39*, 37 kDa; GFP-MAGI2 Tyr746*, 110 kDa; GFP-Toca, 93 kDa; 
FLAG-RapGEF2, 167 kDa. **, non-specific band. 
 
Figure 2. Combined expression of RapGEF2 and MAGI2, but not disease causing 
MAGI2 variants, induce Rap1 activation. (A) Confluent transfected 293T cells were 
exposed briefly to calcium chelation followed by restoration of full calcium-containing 
medium (calcium switch). Cellular lysates were collected both before and after the calcium 
switch and assayed for levels of active Rap1. While there was a generalized increase in 
Rap1 activation in all samples after calcium switch, this response was dramatically 
augmented in cells that expressed both RapGEF2 and MAGI2, but not in cells expressing 
RapGEF2 and disease causing MAGI2 alleles. 293T cells were transfected with the 
following expressions plasmids:  lanes 1 and 6: GFP-MAGI2 WT, lanes 2 and 7: FLAG-
RapGEF2, lanes 3 and 8: GFP-MAGI2 WT and FLAG-RapGEF2, lanes 4 and 9: GFP-
MAGI2 Gly39* and FLAG-RapGEF2, and lanes 5 and 10: GFP-MAGI2 Tyr746* and 
FLAG-RapGEF2. Lower panel shows the western blot densitometric quantification 
comparing relative levels of Rap1 activation between groups. Ratio of active to total Rap1 
was calculated for three individual experiments and then normalized. *P < .025, **P < 
.035, ***P < .03, ****P < .04. Arrow indicates non-specific blotting artifact over 9th lane, 
which was excluded from densitometric analysis. (B) Levels of Rap1 activation were also 
not augmented in cells expressing RapGEF2 and MAGI1. 293T cells were transfected with 
the following plasmids: lane 1: GFP-MAGI2 WT and FLAG-RapGEF2, lane 2: GFP-
MAGI2 Gly39* and FLAG-RapGEF2, lane 3: GFP-MAGI2 Tyr 746* and RapGEF2 and 
lane 4: GFP-MAGI1 and FLAG-RapGEF2. Densitometric quantification of active to total 
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Rap1 was calculated for three separate experiments and then normalized. *P < .02, **P < 
.045, ***P < .025. 
 
Figure 3. Glomerular RapGEF2 expression is lost in podocyte-specific RapGEF2 KO 
mice. (A) Immunostaining for RapGEF2 on kidney sections of control mice demonstrates 
widespread expression in both tubules and podocytes. Its podocyte expression is mainly 
cytoplasmic, where it co-localizes with the podocyte cytoplasmic marker nestin. Scale bar 
low power 50m; high power 10m. (B) In podocyte-specific RapGEF2 KO mice, 
glomerular RapGEF2 expression is absent, but tubular expression preserved. Scale bar low 
power 50m; high power 10m. 
 
Figure 4. Podocyte-specific RapGEF2 KO mice develop FSGS with comparable 
qualitative glomerular features compared to MAGI2 KO mice. (A) Survival curve 
showing age of onset of proteinuria. Urine protein:creatinine ratios were measured weekly 
with the onset of proteinuria defined by a protein:creatinine ratio of greater than 400g/mg 
for two consecutive weeks. (B) Calculated protein:creatinine ratios for RapGEF2 KO mice 
(n=12, at age 20 weeks or at time of sacrifice) and global MAGI2 KO mice (n=4, age 5 
weeks).  Both models develop severe proteinuria. (C) For each mouse with proteinuria, the 
percentage of glomeruli demonstrating glomerulosclerosis on PAS staining was calculated. 
(D) Comparative pathologic analysis of proteinuric RapGEF2 KO mice (age 12 weeks) 
with MAGI2 KO mice (age 5 weeks).  Both models demonstrate focal segmental and 
global glomerulosclerosis, mesangial expansion, and parietal cell proliferation with 
pseudocrescent formation. Original magnification for control: 200X upper, 600X lower. 
Original magnification for RapGEF2 and MAGI2 KO: 200X upper left; 400X upper right 
and middle left; 600X middle right and lower left and right.  Arrow shows parietal cell 
proliferation with pseudocrescent. (E) Electron microscopy reveals comparable qualitative 
features between proteinuric podocyte-specific RapGEF2 KO and MAGI2 KO mice.  Both 
show diffuse foot process effacement, actin cytoskeletal matting parallel to the GBM, and 
simplification and loss of primary and secondary processes. Scale bar low power 5µm, 
high power 2.5µm. Arrow shows actin cytoskeletal matting present in both models. (F) 
Podocyte loss was evident in both MAGI2 and proteinuric RapGEF2 KO mice. The 
number of WT-1 positive cells per glomerular tuft area was determined for 20 glomeruli 
per mouse. n=3 mice per group (*P< .0001, **P<.03, ***P<.03). 
 
Figure 5. RapGEF2 or MAGI2 knockdown in podocytes similarly diminish Rap1 
activation and Rap1 mediated downstream signaling. (A) Human cultured podocytes 
transduced with shRNA expression plasmid targeting RapGEF2 or MAGI2 mRNA 
demonstrate diminished RapGEF2 or MAGI2 protein expression, respectively, compared 
to podocytes expressing a scrambled shRNA. Two distinct shRNA plasmids were used for 
both RapGEF2 and for MAGI2, each with a unique mRNA target sequence.  Levels of 
Rap1 activation induced by calcium switch were dramatically reduced in all four 
knockdown cell lines compared to control cells. Ratio of active to total Rap1 was 
calculated for three individual experiments and then normalized (for control cells versus 
RapGEF2 #1 and #2: *P<.03, **P<.04; for control cells versus MAGI2 #1 and #2: *P<.01 
for both). , , and  indicate major MAGI2 splice isoforms. The asterisk represents a non-
specific band. (B) Western blotting of podocytes transduced as indicated was performed 
after calcium switch. Levels of β1 integrin activation and Erk1/2 phosphorylation (both 
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major Rap1 downstream signals) were substantially diminished. Densitometric ratios of 
active to total 1 integrin was calculated for three individual experiments and then 
normalized. *P<.02, **P<.01, ***P<.001. Quantification combined the band intensities of 
the two isoforms of active 1 integrin (shown by arrows) and compared it to the combined 
intensities of the bands for total 1 integrin. Densitometric quantification for phospho to 
total Erk1/2 is also shown. *P<.03, **P<.02, ***P< .01. (C) RapGEF2 and MAGI2 
knockdown cells migrated more slowly than control cells. The percent wound closure was 
quantified at fixed locations along the scratch. *P<.0001, **P<.002 (each versus controls), 
no significant difference between RapGEF2 and MAGI2. 
 
Figure 6. RapGEF2 or MAGI2 knockdown in podocytes results in similarly high 
rates of apoptosis. (A) Differentiated RapGEF2 and MAGI2 knockdown podocytes were 
cultured for 48 hours under basal conditions, after which adherent and non-adherent cells 
were collected, combined, and then assayed for Annexin V and 7-AAD by FACS analysis. 
Both RAPGEF2 and MAGI2 knockdown podocytes show enhanced levels of apoptosis 
compared to controls.  Experiments were repeated a total of three times using newly grown 
cells each time.  (B) The ratio of Annexin V positive cells relative to controls was 
calculated for each experiment and results averaged. *P=.0005 (RapGEF2 versus control), 
**P=.0002 (MAGI2 versus control), no significant difference between RapGEF2 and 
MAGI2. 
 
Figure 7. Podocytes expressing MAGI2 CNS variants are rescued by pharmacological 
activation of Rap1 (A) Human podocytes were transduced with lentiviral expression 
plasmids carrying full length FLAG-MAGI2, FLAG-MAGI2 pTyr746*, FLAG-MAGI2 
pGly 39*, or with lentiviral vector alone (control). Each podocyte line was fully 
differentiated, and then immunofluorescence was performed using an anti-FLAG antibody. 
Wild type FLAG-MAGI2 robustly accumulated at sites of intercellular contacts. In both of 
the CNS causing MAGI2 variants, however, FLAG-MAGI2 was dramatically mislocalized 
demonstrating punctate protein accumulation throughout the cytoplasm. Control vector 
transduced podocytes showed no immunoreactivity. Scale bar 20m. (B) Each podocyte 
cell line was differentiated for seven days either with or without the potent Rap1 activator, 
8-pCPT-2′-O-Me-cAMP (8-pCPT) and then stained for actin using phalloidin. While 
vector-alone and wild type MAGI2 transduced podocyte lines each demonstrated normal 
morphology and robust actin polymerization, podocytes that expressed either of the human 
MAGI2 disease causing variants demonstrated severe abnormalities of cellular 
morphology and dramatically diminished actin content (top row). However, when cultured 
in the presence of 8-pCPT, the MAGI2 mutant phenotype was completely rescued with 
normalization of cell shape and restoration of robust actin polymerization (lower row). 
Scale bar 50m. (C) Quantification of actin staining is shown. Five hundred phalloidin 
stained cells were assessed for each podocyte line by a blinded observer. Cells were 
considered positive when actin filaments were robust throughout the entire cell. ** 
P<.0001 (each versus control or MAGI2); NS, not significant. (D) Podocyte lines were 
differentiated with either vehicle or 8-pCPT and then protein was harvested for active 
Rap1 pull down assays or western blotting. Levels of active Rap1 were substantially 
reduced in podocytes expressing mutant MAGI2 variants, but in the presence of 8-pCPT 
were restored to levels similar to podocytes expressing wild type MAGI2. Densitometric 
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quantification of active to total Rap1 was calculated for three separate experiments and 
then normalized. *P<.02, **P<.01; NS, not significant. 
 
Figure 8. Immunohistochemistry of kidney from congenital nephrotic syndrome 
patients caused by MAGI2 mutations is consistent with reduced podocyte Rap1 
signaling. (A) Immunostaining for the Rap1 downstream effector phospho-Erk1/2 was 
performed on paraffin embedded human kidney sections.  Representative images are 
shown. Scale bar low power 100m; high power 20m (B) Quantification of glomerular 
staining intensity was calculated and is shown as a fold change relative to MAGI2 CNS.  
Podocyte phospho-Erk1/2 staining is severely reduced in MAGI2 CNS patients compared 
to controls, but is only intermediately reduced in idiopathic FSGS patients.  Intensity of 
total Erk1/2 staining is identical between the groups. Total number of glomeruli analyzed: 
n=60 control (20 glomeruli from each of three individual patients), n=72 idiopathic FSGS 
(12 glomeruli from each of six individual patients, n=50 MAGI2 CNS (two individual 
patients, 32 glomeruli from nephrectomy sample, 18 glomeruli from biopsy sample) (*P< 
.001, **P<.004, ns is no significant difference). 
 
Figure 9. The interaction between MAGI2 and RapGEF2 is a critical upstream signal 
for Rap1 activation in podocytes. In normal podocytes, the interaction of RapGEF2 with 
MAGI2 is required to maintain sufficient levels of activated Rap1 and essential Rap1 
downstream signals (left panel).  In patients with CNS caused by mutations in MAGI2, 
however, the interaction between RapGEF2 and MAGI2 is lost and cannot induce Rap1 
activation (right panel). This causes a reduction of critical Rap1-mediated downstream 
signals and over time induces podocyte injury and ultimately FSGS.  
 
 
 
 
 
